Wire · opportunities
Extension Studies Are Not Optional Data, They're the FDA's Long-Term Safety Net
◆ Sectors
Biotech
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 8 November 2026 · Fusion42 review
Extension studies are critical to assess long-term treatment durability and detect delayed adverse events that pivotal trials cannot capture, and must be integrated into trial design from the start rather than treated as optional add-ons.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You must build extension studies into your Phase 3 protocols now; delaying this step risks regulatory pushback and unsafe datasets that could derail approval or safety claims.
◆ Coverage
1 source · 8 Nov 2026
◆ Related on Wire
◆ Topics
Biotechfdaclinical-trialsextension-studiesdrug-safetyregulatory-compliance